Autopsy report · NCT02658916

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

Cause of deathFutility Automatic label, confidence 0.9, unverified. How labels are made.

“251PP301(NCT03068468) primary endpoint was not met;further development of Gosuranemab BIIB092 in progressive supranuclear palsy will not be pursued.”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 month before it started.
Ran for about 4 years 1 month before it stopped.
47 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Biogen
Sponsor type: Industry
Conditions: Supranuclear Palsy, Progressive
Interventions: BIIB092
Participants: 47
Sites: 13
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.